Frances Terry Archives - EpiVax

Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

by Elena Iemma | Sep 12, 2023

Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

by Elena Iemma | May 1, 2023

Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune Cell-Engagers

Poster: Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications

by Annie De Groot | Sep 23, 2020

Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications

T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines

T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines

by Annie De Groot | Apr 9, 2020

2020 Bandrick et al. EpiCC